58
Participants
Start Date
December 11, 2018
Primary Completion Date
November 8, 2022
Study Completion Date
November 8, 2022
isatuximab SAR650984
"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
cemiplimab REGN2810
"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
Investigational Site Number :6200003, Porto
Investigational Site Number :3800003, Rozzano
Investigational Site Number :2500005, Dijon
Investigational Site Number :3800006, Brescia
Investigational Site Number :7240004, Madrid / Madrid
Investigational Site Number :2500007, Pessac
Investigational Site Number :2500004, Montpellier
Investigational Site Number :3800002, Bologna
Investigational Site Number :1580002, Taichung
Investigational Site Number :2500002, Nantes
Investigational Site Number :2500001, Villejuif
Investigational Site Number :5280002, Amsterdam
Investigational Site Number :5280001, Maastricht
Investigational Site Number :6200002, Coimbra
Investigational Site Number :6200004, Lisbon
Investigational Site Number :4100001, Gangnam-gu
Investigational Site Number :4100002, Seoul
Investigational Site Number :7240003, Barcelona
Investigational Site Number :7240005, Barcelona
Investigational Site Number :7240002, L'Hospitalet de Llobregat
Lead Sponsor
Sanofi
INDUSTRY